Last edition
News about "Insmed Incorporated"
FDA Grants Priority Review to Insmed's Arikayce sNDA
Insmed’s Arikayce sNDA receives FDA Priority Review for the treatment of MAC lung disease, with a PDUFA target action date of January 28, 2027.
Insmed Incorporated | 22/09/2026 | By News Bureau
Insmed's Brinsupri Wins Japan Approval for Non-Cystic Fibrosis Bronchiectasis
Insmed’s Brinsupri (brensocatib) has secured MHLW approval in Japan for non-cystic fibrosis bronchiectasis, expanding access to a new treatment option for patients with the chronic and progressive lung disease.
Insmed Incorporated | 26/08/2026 | By News Bureau | 116
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy